## In the Claims

Please cancel claims 1-41 without prejudice or disclaimer.

Please add new claims 42-57 as noted below.

1-41 (Canceled herewith)

42. (New) A composition comprising an immunostimulatory nucleic acid, having a sequence including at least the following formula:

$$5' \text{ TCNT}X_1X_2\text{CpG}X_3X_4 \text{ } 3'$$

wherein X_1, X_2, X_3, and X_4 are nucleotides, N is a nucleic acid sequence composed of from about 0-25 nucleotides, wherein at least one nucleotide has a phosphate backbone modification, and wherein the nucleic acid has less than or equal to 100 nucleotides, and wherein C is unmethylated.

43. (New) The composition of claim 42, wherein the phosphate backbone modification is a phosphorothioate or phosphorodithioate modification.

44. (New) The composition of claim 42, wherein the phosphate backbone modification occurs at the 5' end of the nucleic acid.

45. (New) The composition of claim 42, wherein the phosphate backbone modification occurs at the 3' end of the nucleic acid.

46. (New) The composition of claim 42, wherein X_1X_2 are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X_3X_4 are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA.

47. (New) The composition of claim 42, wherein X_1X_2 are nucleotides selected from the group consisting of: GpT, GpG, GpA and ApA and X_3X_4 are nucleotides selected from the group consisting of: TpT, CpT or GpT.

48. (New) The composition of claim 42, wherein X_1X_2 are GpA and X_3X_4 are TpT.

49. (New) The composition of claim 42, wherein X_1X_2 are both purines and X_3X_4 are both pyrimidines.

50. (New) The composition of claim 42, wherein X_1X_2 are GpA and X_3X_4 are both pyrimidines.

51. (New) The composition of claim 42, wherein the immunostimulatory nucleic acid is 8 to 40 nucleotides in length.

52. (New) The composition of claim 42, wherein the nucleic acid sequence includes at least one of the following sequences:

ATCGACTCTCGAGCGTTCTC   (SEQ ID No. 15)

TCCATGTCGGTCCTGCTGAT (SEQ ID No. 32)

TCCATGTCGGTZCTGATGCT (SEQ ID No. 31)

ATCGACTCTCGAGCGTTZTC (SEQ ID No. 18)

TCCATGTCGGTCCTGATGCT (SEQ ID No. 28)

TCCATGACGGTCCTGATGCT (SEQ ID No. 35)

TCCATGGCGGTCCTGATGCT (SEQ ID No. 34)

TCCATGACGTTCCTGATGCT (SEQ ID No. 7)

TCCATGTCGTTCCTGATGCT (SEQ ID No. 38)

GGGGTCAGTCTTGACGGGG (SEQ ID No. 41)

TCCATGTCGCTCCTGATGCT (SEQ ID No. 37)

TCCATGTCGATCCTGATGCT (SEQ ID No. 36)

TCCATGCCGGTCCTGATGCT (SEQ ID No. 33)

TCCATAACGTTCCTGATGCT (SEQ ID No. 3)

TCCATGACGTTCCTGATGCT (SEQ ID No. 7)

TCCATGACGTCCCTGATGCT (SEQ ID No. 39)

TCCATCACGTGCCTGATGCT (SEQ ID No. 48)

TCCATGACGTTCCTGACGTT (SEQ ID No. 10)

ATGACGTTCCTGACGTT (SEQ ID No. 70)

TCTCCCAGCGCGCGCCAT (SEQ ID No. 72)

TCCATGTCGTTCCTGTCGTT (SEQ ID No. 73)

TCCATAGCGTTCCTAGCGTT (SEQ ID No. 74)

TCCTGACGTTCCTGACGTT (SEQ ID No. 76)

TCCTGTCGTTCCTGTCGTT (SEQ ID No. 77)

TCCTGTCGTTCCTTGTCGTT (SEQ ID No. 52)

TCCTTGTCGTTCCTGTCGTT (SEQ ID No. 121)

TCCTGTCGTTTTTGTCGTT (SEQ ID No. 53)

TCGTCGCTGTTGTCGTTTCTT (SEQ ID No. 120)

TCCATGCGTTGCGTTGCGTT (SEQ ID No. 81)

TCCACGACGTTTTCGACGTT (SEQ ID No. 82)

TCGTCGTTGTCGTTGTCGTT (SEQ ID No. 47)

TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID No. 46)

TCGTCGTTGTCGTTTTGTCGTT (SEQ ID No. 49)

GCGTGCGTTGTCGTTGTCGTT (SEQ ID No. 56)

TGTCGTTTGTCGTTGTCGTT (SEQ ID No. 48)

TGTCGTTGTCGTTGTCGTTGTCGTT (SEQ ID No. 84)

TGTCGTTGTCGTTGTCGTT (SEQ ID No. 50)